博大绿泽(01253.HK)组合营建设PPP项目
中国绿地博大绿泽(01253.HK)公布,有关公司为2019年5月6日中标PPP项目一事,私人订约方(博大绿泽生态、中博建设、上海祝琛、黑龙江华龙及镇平水利)订立合营协议,据此,订约方同意(i)组成合营公司以建设PPP项目;及(ii)规管彼等各自於合营公司的权利及责任。
合营公司之注册资本将为1.11亿元人民币,镇平水利、博大绿泽生态、中博建设、上海祝琛及黑龙江华龙将分别按比例出资10%、25%、0.5%、64.4%及0.1%。博大绿泽生态、中博建设及上海祝琛为中国绿地博大绿泽旗下公司;黑龙江华龙及镇平水利为独立第三方。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.